Menu
Search Close

News

Investor Day Agenda

30th September 2013

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013. Details of the event are:

Location 

FTI Consulting
Holborn Gate
26 Southampton Buildings
London, WC2A 1PB

10.45

Registration with refreshments

11.00

Introduction David Evans,

Scancell Non-Executive Chairman

11.05

Cancer immunotherapy

Prof Peter Stern, Head of the Immunology Group, Paterson Institute for Cancer Research, University of Manchester

11.20

Scancell corporate update

Dr Richard Goodfellow, Joint CEO of Scancell

11.30

SCIB1 trial update and introduction to Moditope™

Prof Lindy Durrant, Joint CEO of Scancell

11.45

Q&A

12.00

Interactive panel discussion

Led by Prof Karol Sikora, Dean of Medicine , University of Buckingham; Honorary Consultant Oncologist at Hammersmith Hospital

Panellists include:

Prof Lindy Durrant,

Prof Peter Stern,

Dr Steve Chan, Consultant Oncologist, City Hospital, Nottingham University

and Prof Christian Ottensmeier, Dept. of Experimental Medicine, University of Southampton

12.45

Buffet lunch

13.30

Close

For Further Information:

Scancell Holdings Plc

 

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO       

+ 44 (0) 20 7831 3113

 

 

Cenkos Securities:

 

Camilla Hume / Stephen Keys

+44 (0) 20 7397 8900

 

 

FTI Consulting

 

Mo Noonan / Eleanor Clarke

+44 (0) 20 7831 3113


About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Webcasts, Interviews and Media Coverage

Scancell raises £5mln in 'most successful round they've ever had' - CEO Richard Goodfellow

Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP) talks through with Proactive Investors their £5mln raise to fund clinical work on their pipeline of cancer immune-therapies.

Fri, 12 May 2017 07:57:00

Scancell Holdings raises £5mln as pace of clinical work quickens

The money will support clinical work on its pipeline of cancer immunotherapies and in particular Modi-1, the first product from its Moditope platform.

Thu, 11 May 2017 12:00:00

Scancell boss 'very excited' about collaboration deal with leading US lung cancer foundation

Scancell Holdings Plc (LON:SCLP) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.

CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.

Wed, 01 Feb 2017 09:53:00